FibroGen, Inc. (FGEN)
NASDAQ: FGEN · IEX Real-Time Price · USD
2.350
-0.230 (-8.91%)
At close: Mar 28, 2024, 4:00 PM
2.388
+0.038 (1.62%)
After-hours: Mar 28, 2024, 7:49 PM EDT

FibroGen Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 2012
Net Income
-284.23-293.65-290.02-189.29-76.97-86.42-120.88-58.07-85.78-59.5
Upgrade
Depreciation & Amortization
9.9310.614.8122.0521.456.566.16.045.684.47
Upgrade
Share-Based Compensation
50.7765.671.1672.7266.2752.1437.5432.1327.6818.7
Upgrade
Other Operating Activities
-91.4971.52121.82176.13-89.46-48.4310.722733.8558.75
Upgrade
Operating Cash Flow
-315.02-145.93-82.2381.6-78.71-76.14-66.517.11-18.5722.41
Upgrade
Operating Cash Flow Growth
----------13.52%
Upgrade
Capital Expenditures
-2.52-3.74-5.19-3.99-5.76-7.84-8.5-1.25-1.98-8.11
Upgrade
Acquisitions
0.66-35-25-2.83000000
Upgrade
Change in Investments
155.52127.85-396.79459.31125.77-514.2978.367.87-3.89-99.18
Upgrade
Investing Cash Flow
153.6689.12-426.97452.49120.02-522.1269.876.62-5.87-107.29
Upgrade
Share Issuance / Repurchase
52.144.1812.737.8320.7829.85506.129.8814.99177.63
Upgrade
Debt Issued / Paid
70.8547.76-5.89-13.02-12.33-0.36-0.4-0.4-0.4-0.4
Upgrade
Other Financing Activities
-0.24-5.17-7.37-11.46-12.75-15.61-9.24-2.74-2.24-3.14
Upgrade
Financing Cash Flow
122.7546.78-0.5613.34-4.313.88496.476.7412.35174.09
Upgrade
Exchange Rate Effect
-3.4-5.482.64.7-0.01-0.010.05-0.01-0.04-0.09
Upgrade
Net Cash Flow
-42.01-15.52-507.17552.1337.01-584.4499.8820.46-12.1389.12
Upgrade
Free Cash Flow
-317.54-149.67-87.4277.61-84.46-83.98-75.015.86-20.5514.31
Upgrade
Free Cash Flow Growth
----------25.15%
Upgrade
Free Cash Flow Margin
-214.91%-106.35%-37.15%44.02%-32.92%-39.44%-57.26%3.20%-11.36%10.40%
Upgrade
Free Cash Flow Per Share
-3.26-1.60-0.950.86-0.97-1.00-1.030.09-0.340.76
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).